철근콘크리트 보의 장기처짐에 대한 연구

송상용 ( Song Sang-yong ),김선영 ( Kim Sun-young ),이수곤 ( Lee Soo-gon ) 한국구조물진단유지관리공학회 2002 한국구조물진단유지관리공학회 학술발표대회 논문집 Vol.6 No.2

According to the simplified code expressions including ACI and CEB-FIP(1990), long-term deflections of reinforced concrete beams can be computed by multiplying initial deflection by any factor. To this date, however, most of studies on the long-term deflections have been mainly carried out for beams. Therefore, it is necessary to study on the deflections of beams at the frame structure. To examine long-term deflections of beams, the experiment frame was made in accordance with the general construction sequence; the placement of concrete, form removal, reshoring, shore removal, and the additional load application. Test result showed that the current ACI code and CEB-FIP(1990) code did predict well. Furthermore, analysis method using the creep and shrinkage model proposed by ACI 318-⑴ and CEB-FEP(1990) had not difference with each other but had predicted a little greater than test results.

자궁경부 원추형 생검수술후 재발 방지를 위한 인유두종바이러스 검사 시기와 대책에 대한 고찰

김소영 ( So Young Kim ),송은섭 ( Eun Seop Song ),최석진 ( Suk Jin Choi ),김근성 ( Keun Sung Kim ),이기은 ( Ki Eun Lee ),김석모 ( Seok Mo Kim ),박지현 ( Jee Hyung Park ),송상용 ( Sang Yong Song ),송윤섭 ( Yun Seob Song ) 대한산부인과학회 2006 Obstetrics & Gynecology Science Vol.49 No.7

목적: 자궁경부 원추형 생검수술후 언제 인유두종바이러스 (HPV) 검사를 하는 것이 좋은가를 알고자 하였다. 연구방법: 1997년부터 2004년까지 A병원 산부인과에서 원추형생검을 Large Loop Excisions of the Transformation Zone (LLETZ)에 의해 시행한 환자를 대상으로, 시술 전 Pap과 HPV 아형을 HPV oligonucleotide microarray (Biomedlab Co., Seoul, South Korea)를 이용하여 검사하였고, 시술 후 3개월마다 HPV 아형검사를 검사하였다. 결과: 8년간 120명의 환자가 이 연구에 참여하였다. 8명은 병변이 없었고, 9명은 자궁경부 상피내종양 (CIN) 1, 17명은 CIN2, 74명은 CIN3, 10명은 미세침윤암, 그리고 2명은 선암이 자궁경부상피내에 국한되어 있었다. LLETZ를 하기 전에 HPV는 85.0%에서 양성이고, 가장 흔한 아형은 16번으로 전체의 40.8%를 차지하였다. LLETZ후에는 1,307 개월에 걸쳐서 190회의 HPV 검사가 실행되었으며 (평균 1회 검사당 6.9개월), 95회 (79.2%)에서는 음성을 25회 (20.8%)에서는 양성을 보였다. 그리고 음성 환자들의 약 80%에서 LLETZ후 6개월 내에 음성을 보였다. 결론: LLETZ로 HPV 음성 되는 환자의 80%가 6개월 내 음성이 되므로, HPV 아형 검사는 시술 후 6개월째부터 하는 것이 좋을 것으로 사료된다. Objective: To know when human papillomavirus (HPV) testing should be done after conization. Methods: Between 1997 to 2004, Large Loop Excisions of the Transformation Zone (LLETZ) were done for conization to women with cervical pathology at A University Hospital. The Pap and HPV typing were done before LLETZ procedures. After conizations, HPV typing were planned to be done every 3 months. Every HPV typing was done by HPV oligonucleotide microarray (Biomedlab Co., Seoul Korea). Results: For 8 years, 120 LLETZ were enrolled in this study. There were 8 cases of no neoplasm, 9 cases of CIN 1, 17 cases of CIN 2, 74 cases of CIN 3, 10 cases of microinvasive cervix cancer, and 2 cases of adenocarcinoma in situ. HPV DNA before LLETZ procedures was found about 85.0% and subtype 16 was the most common type among the patients with cervical lesion (40.8%). After LLETZ, 190 HPV typing were done through 1,307 total months (average, 6.9 months/typing). 95 (79.2%) cases had negative results, and 25 (20.8%) cases had positive results. Our data showed that, after conization, about 80% turned out to negative in 6 months. Conclusion: Our data suggested HPV DNA testing should be done after 6 months of LLETZ, as about 80% were destined to negative in 6 months.

직장암에 대한 수술 전 동시병용 방사선-항암 화학요법: 초기 치료결과 보고

신성수,안용찬,전호경,이우용,강원기,박영석,박준오,송상용,임도훈,박원,이정은,강민규,박영제,Shin, Seong-Soo,Ahn, Yong-Chan,Chun, Ho-Kyung,Lee, Woo-Yong,Kang, Won-Ki,Park, Young-Suk,Park, Joon-Oh,Song, Sang-Yong,Lim-Do-Hoon,Park, Won,Lee, Jun 대한방사선종양학회 2003 Radiation Oncology Journal Vol.21 No.2

목적: 수술 전 동시병용 방사선-항암 화학 요법의 초기 치료성적과 급성 부작용에 대해 알아보고자 하였다. 대상 및 방법: 1999년 6월부터 2002년 4월까지 T3또는 T4 병기의 직장암으로 진단 받고 완전절제가 어렵거나, 종양이 하부직장에 위치하여 수술 시 항문 괄약근의 보존이 불가능하리라고 예견된 40명의 환자에게 수술 전 동시병용 방사선-항암 화학요법을 적용하여 37명의 환자가 수술 전 치료방침을 완료하였다. 방사선치료는 전 골반부에 일일 1.8 Gy씩 5주간에 45 Gy를 엎드린 자세로 조사하였다. 항암 화학요법은 경구 UFT와 Leucovorin (LV)(12명), 정주 5-fluorouracil (FU)와 LV (10명), 정주 5-FU 단독요법(일시 정주 10명, 지속 정주 5명)을 각각 시행하였다. 수술은 수술 전 치료 종료 후 4$\~$6주경에 예정하였으며 35명에 대해서 수술을 시도하였다. 결과: 본 연구의 수술 전 방사선-항암 화학요법에 대한 순응도는 매우 높았. (92.5$\%$, 37/40). 수술 전에 간과 폐에 새로운 원격전이가 확인된 2명을 제외한 35명의 환자에서 절제수술을 시도하였고, 22명(62.9$\%$)에서 항문 괄약근의 보존이 가능하였으나, 2명(5.7$\%$)은 개복 후 절제수술을 포기하였다. 절제수술을 시행한 33명 중 30명은 육안적 완전절제를, 1명은 육안적 불완전절제를 시행하였으며 2명은 병리소견에 관한 정보를 얻을 수 없었다. 수술 및 병리소견에 근거한 병기하강률은 45.5$\%$ (15/33), 절제연 음성 완전절제율은 78.8$\%$ (26/33)였다. 수술 전 방사선치료 도중 급성 부작용으로 Grade 3$\~$4 호중구 감소가 4명(10.8$\%$)에서 발생하였다. 절제수술 후 국소 재발이 12.1$\%$ (4/33), 수술 전 치료방침 완료 후 원격 전이는 21.6$\%$ (8/37)에서 각각 나타났으며, 3년 생존율은 87$\%$였다. 결론: 직장암에 대한 수술 전 동시병용 방사선-항암 화학요법은 낮은 부작용으로 높은 수술절제율, 병기하강률, 완전절제율, 항문 괄약근 보존율 등을 얻을 수 있는 효과적인 방법으로 판단되며 앞으로 장기간에 걸친 추적관찰을 요한다. Purpose: To report the early results of preopeartive concurrent radio-chemotherapy (CRCT) for treating rectal cancer. Materials and Methods: From June 1999 to April 2002, 40 rectal cancer patients who either had lesions with a questionable resectability or were candidates for sphincter-sacrificing surgery received preoperative CRCT. Thirty-seven patients completed the planned CRCT course. 45 Gy by 1.8 Gy daily fraction over 5 weeks was delivered to the whole pelvis in the prone position. The chemotherapy regimens were oral UFT plus oral leucovorin (LV) in 12 patients, intravenous bolus 5-FU plus LV in 10 patients, and intravenous 5-FU alone in 15 patients (bolus infusion in 10, continuous infusion in 5). Surgery was planned in 4$\~$6 weeks of the completion of the preoperative CRCT course, and surgery was attempted in 35 patients. Results: The compliance to the current preoperative CRCT protocol was excellent, where 92.5$\%$ (37/40) completed the planned treatment. Among 35 patients, in whom surgery was attempted after excluding two patients with new metastatic lesions in the liver and the lung, sphincter-preservation was achieved in 22 patients (62.9$\%$), while resection was abandoned during laparotomy in two patients (5.7$\%$). Gross complete resection was peformed in 30 patients, gross incomplete resection was peformed in one patient, and no detailed information on the extent of surgery was available in two patients. Based on the surgical and pathological findings, the down-staging rate was 45.5$\%$ (15/33), and the complete resection rate with the negative resection margin 78.8$\%$ (26/33). During the CRCT course, grade 3 $\~$4 neutropenia developed in four patients (10.8$\%$). Local recurrence after surgical resection developed in 12.1$\%$ (4/33), and distant metastases after the preoperative CRCT start developed in 21.6$\%$ (8/37). The overall 3-years survival rate was 87$\%$. Conclusion: Preoperative CRCT in locally advanced rectal cancer is well tolerated and can lead to high resection rate, down-staging rate, sphincter preservation rate, however, longer term follow-up will be necessary to confirm these results.

간세포암종의 간절제술 후 장기 예후인자 - 단변량 및 다변량 분석

박철근(Cheol Keun Park),장우영(Woo Young Jang),이종임(Jong Im Lee),최문석(Moon Seok Choi),조재원(Jae Won Cho),김선우(Seon Woo Kim),송상용(Sang Yong Song) 대한소화기학회 2002 대한소화기학회지 Vol.39 No.1

Background/Aims: We assessed prognostic factors affecting cumulative survival rate and recurrence-free survival rate after hepatic resection of hepatocellular carcinoma (HCC). Methods: Univariate and multivariate analyses were performed in 108 consecutive patients with HCC who underwent curative hepatic resection between November 1994 and March 1998. Results: The cumulative survival rates were 89.8%, 75.5%, and 56.6% at 1, 3, 5 years, respectively. The cumulative recurrence-free survival rates were 78.9%, 62.1%, and 53.0% at 1, 3, 5 years, respectively. The patients who had preoperative serum α-FP ≤ 20ng/mL showed high cumulative recurrence-free survival rates in univariate (p=0.020) and multivariate (p=0.061) analysis. Single tumor was associated with increased cumulative survival rates (p=0.034) and cumulative recurrence-free survival rates (p=0.029) in multivariate analysis. The presence of tumor capsule was associated with increased cumulative recurrence-free survival rates in univariate (p=0.031) and multivariate (p=0.030) analysis. Conclusions: By these results, resection alone is unlikely to cure HCC patients with multiple tumors or no tumor capsule. Preoperative serum α-FP level may be of prognostic significance in patients with HCC. (Korean J Gastroenterol 2002;39:33-39)

위암에서 Cyclooxygenase - 2 와 Inducible Nitric Oxide Synthase 의 발현

박동일(Dong Il Park),이종철(Jong Chul Rhee),손희정(Hee Jung Son),송상용(Sang Yong Song),김영호(Young Ho Kim),이풍렬(Poong Lyul Rhee),김재준(Jae J . Kim),백승운(Seung Woon Paik),최규완(Kyoo Wan Choi),손태성(Tae Sung Son) 대한소화기학회 2001 대한소화기학회지 Vol.38 No.3

Background/Aims: It has been expected that chronic expression of cyclooxygenase-2(COX-2) and inducible nitric oxide synthase(Inos) may play an important role in gastric carcinogenesis. The purpose of our study was to investigate the role of COX-2 and Inos Mrna expression in gastric carcinogenesis and the correlation between the expression of COX-2 and Inos Mrna in patients with gastric cancer. Methods: Twenty-three gastric carcinoma tissue specimens and their adjacent normal mucosa specimens were obtained from surgical resection. The expression of COX-2 and Inos Mrna were examined by comparative reverse transcriptase-polymerase chain reaction. Results: COX-2 and Inos Mrna were expressed significantly higher in gastric cancer tissues than in adjacent normal tissues. There was a significant correlation between the level of COX-2 and Inos Mrna in carcinoma tissues. There was no significant correlation between the level of COX-2 or Inos Mrna expression and clinicopathological parameters such as tumor size, depth of invasion, differentiation, Laurens classification, lymph node metastasis, perineural and vascular invasion in these patients. Conclusions: The expression of COX-2 and Inos may be one of the factors that contribute to the early stage of gastric carcinogenesis. (Korean J Gastroenterol 2001;38:161-168)

난소에서 발생한 Hepatoid Carcinoma

최세미(Se Mi Choi),박창수(Chang Soo Park),오성희(Sung Hee Oh),김태중(Tae Joong Kim),송상용(Sang Young Song),안긍환(Geung Hwan Ahn),배덕수(Duk Soo Bae),이제호(Je Ho Lee) 대한산부인과학회 2000 Obstetrics & Gynecology Science Vol.43 No.1

Hepatoid carcinoma is a rare type of malignant tumor resembling hepatocellular carcinoma that arises in extrahepatic sites.(stomach, lung, ovary, pancreas, bladder and renal pelvis). Hepatoid carcinoma of the ovary is an extremely rare ovarian tumor, first described by Ishikura and Scully in 1987. Histologically it is important to differentiate this entity from other oxyphil tumors of the ovary as it requires aggressive treatment. We have experienced a case of hepatoid carcinoma of the ovary in 69-year-old postmenopausal woman, who has been treated with operation and adjuvant Taxol - cisplatin chemotherapy. We present this case with brief review of literatures.

위암에서 TGF - 1 과 TGF - 2 형 수용체의 역할

박동일(Dong Il Park),손희정(Hee Jung Son),송상용(Sang Yong Song),최원혁(Won Hyeok Choe),임윤정(Yun Jeong Lim),박상종(Sang Jong Park),김재준(Jae J . Kim),김영호(Young Ho Kim),이풍렬(Poong Lyul Rhee),백승운(Seung Woon Paik),이종철(Jong 대한내과학회 2001 대한내과학회지 Vol.61 No.4

N/A Background: Transforming growth factor-beta (TGF-β) is a potent inhibit or of epithelial cell growth. However, carcinoma cells, unlike normal cells, can escape from negative regulation by TGF-β through lack of expression or mutation of TGF-β receptor gene. In this study, we investigated the role of TGF-β1 and TGF-β type 2 receptors (TβR-2) in the progression of gastric cancer. Methods: We analyzed TGF-β1 and TβR-2 mRNA expression semi-quantitatively, measured by comparative RT-PCR using GAPDH, in 23 patients who underwent gastric resection for gastric cancer. We analyzed the relationship between the clinicopathologic findings and the level of the TGF-β1 and TβR-2 mRNA expression in carcinoma tissues and in adjacent normal tissues of gastric cancer. Results: (1) TGF-β1 and TβR- 2 mRNA were expressed in all of the carcinoma tissues and adjacent normal tissues without statistical difference in the level of the expression. (2) The level of TGF-β1 mRNA expression was higher in patients with early gastric cancer , negative lymph nodes or negative perineural invasion. There was no significant correlation between the level of TGF-β1 mRNA expression and several parameters such as age, gender, tumor size, differentiation, Lauren's classification, and vascular invasion. (3) There was no significant correlation between the level of TβR-2 mRNA expression and several prognostic variables described above. (4) There was significant correlation between the level of TGF-β1 and TβR-2 mRNA in carcinoma tissues. Conclusion: The above data indicates that TGF-β1 may contribute in the early stages of gastric carcinogenesis. Further studies are required to clarify the role of TGF-β1 in gastric carcinogenesis. (Korean J Med 61:409-416, 2001)

직장암에 대한 수술 전 동시병용 방사선-항암 화학요법

신성수(Seong Soo Shin),안용찬(Yong Chan Ahn),전호경(Ho Kyung Chun,이우용(WooYong Lee),강원기(Won Ki Kang),박영석(Young Suk Park),박준오(Joon Oh Park),송상용(Sang Yong Song),임도훈(Do Hoon Lim, 박원(Won Park),이정은(Jung Eun Lee),강민규 대한방사선종양학회 2003 Radiation Oncology Journal Vol.21 No.2

목 적: 수술 전 동시병용 방사선-항암 화학 요법의 초기 치료성적과 급성 부작용에 대해 알아보고자 하였다. 대상 및 방법: 1999년 6월부터 2002년 4월까지 T3 또는 T4 병기의 직장암으로 진단 받고 완전절제가 어렵거나, 종양이 하부직장에 위치하여 수술 시 항문 괄약근의 보존이 불가능하리라고 예견된 40명의 환자에게 수술 전 동시병용 방사선-항암 화학요법을 적용하여 37명의 환자가 수술전 치료방침을 완료하였다.방사선치료는 전 골반부에 일일 1.8 Gy씩 5주간에45 Gy를 엎드린 자세로 조사하였다. 항암 화학요법은 경구 UFT와 Leucovorin(LV)(12명),정주 5-fluorouracil(FU)와 LV (10명), 정주 5-FU 단독요법(일시 정주 10명, 지속 정주5명)을 각각 시행하였다. 수술은 수술 전 치료 종료후 4˜6주경에 예정하였으며 35명에 대해서 수술을 시도하였다. 결 과: 본 연구의 수술 전 방사선-항암 화학요법에 대한 순응도는 매우 높았다(92.5%, 37/40). 수술 전에 간과폐에 새로운 원격전이가 확인된 2명을 제외한 35명의 환자에서 절제수술을 시도하였고, 22명(62.9%)에서 항문괄약근의 보존이 가능하였으나, 2명(5.7%)은 개복 후 절제수술을 포기하였다. 절제수술을 시행한 33명 중 30명은 육안적 완전절제를, 1명은 육안적 불완전절제를 시행하였으며 2명은 병리소견에 관한 정보를 얻을 수 없었다. 수술 및 병리소견에 근거한 병기하강률은 45.5% (15/33), 절제연 음성 완전절제율은 78.8% (26/33)였다.수술전 방사선치료 도중 급성부작용으로 Grade 3˜4 호중구 감소가 4명(10.8%)에서 발생하였다.절제수술 후 국소재발이 12.1%(4/33), 수술 전 치료방침 완료 후 원격전이는 21.6% (8/37)에서 각각 나타났으며, 3년 생존율은 87%였다. 결 론: 직장암에 대한 수술전 동시병용 방사선-항암 화학요법은 낮은 부작용으로 높은 수술절제율,병기하강률,완전절제율, 항문 괄약근 보존율 등을 얻을 수 있는 효과적인 방법으로 판단되며 앞으로 장기간에 걸친 추적관찰을 요한다. Purpose: To report the early results of preopeartive concurrent radio-chemotherapy (CRCT) for treating rectal cancer. Materials and Methods: From June 1999 to April 2002, 40 rectal cancer patients who either had lesions with a questionable resectability or were candidates for sphincter-sacrificing surgery receivedpreoperative CRCT. Thirty-sevenpatients completed the planned CRCT course. 45 Gy by 1.8 Gy daily fraction over 5 weeks was delivered to the whole pelvis in the prone position. The chemotherapy regimens were oral UFT plus oral leucovorin (LV) in 12 patients, intravenous bolus 5-FU plus LV in 10 patients, and intravenous 5-FU alone in 15 patients (bolus infusion in 10, continuous infusion in 5). Surgery was planned in 4˜6 weeks of the completion of the preoperative CRCT course, and surgery was attempted in 35 patients. Results: The compliance to the current preoperative CRCT protocol was excellent, where 92.5% (37/40) completed the planned treatment. Among 35 patients, in whom surgery was attempted after excluding two patients with new metastatic lesions in the liver and the lung, sphincter-preservation was achieved in 22 patients (62.9%), while resection was abandoned during laparotomy in twopatients (5.7%). Gross complete resection was performed in 30 patients, gross incomplete resection was performed in one patient, and no detailed information on the extent of surgery was available in two patients. Based on the surgical and pathological findings, the down-staging rate was 45.5% (15/33), and the complete resection rate with the negative resection margin 78.8% (26/33). During the CRCT course, grade 3˜4 neutropenia developed in four patients (10.8%). Local recurrence after surgical resection developed in 12.1% (4/33), and distant metastases after the preoperative CRCT start developed in 21.6% (8/37). The overall 3-years survival rate was 87%. Conclusion: Preoperative CRCT in locally advanced rectal cancer is well tolerated and can lead to high resection rate, down-staging rate, sphincter preservation rate, however, longer term follow-up will be necessary to confirm these results.

자궁경부 편평세포암종에서 TADG-15 단백의 발현에 관한 연구

이선주 ( Sun Joo Lee ),이정원 ( Jeong Won Lee ),민정애 ( Jung Ae Min ),박창수 ( Chang Soo Park ),김병기 ( Byoung Gie Kim ),이제호 ( Je Ho Lee ),배덕수 ( Duk Soo Bae ),이지은 ( Ji Eun Lee ),송상용 ( Sang Yong Song ),손영수 ( Young 대한산부인과학회 2004 Obstetrics & Gynecology Science Vol.47 No.12

목적 : Tumor-associated differentially expressed gene-15 (TADG-15)는 상피성 종양의 진행에 관여하는 상피 기원의 막성 serine 단백분해효소이다. 본 연구의 목적은 자궁경부 편평세포암에서 TADG-15의 발현 양상을 알아보고 림프절 전이 여부에 따른 발현의 차이를 조사함에 있다. 연구 방법 : 표본은 침윤성 자궁경부 편평세포암 환자를 대상으로 림프절 전이가 있거나 또는 없는 환자 각각 20명으로부터 채취 Objective : Tumor-associated differentially expressed gene-15 (TADG-15/Matriptase/MT-SP1) is an epithelial-derived, integral serine protease which has been implicated in the progression of epithelial tumors. The aims of this study were to evaluate the exp

동맥류를 동반한 다발성 동맥 섬유근성 이형증식증

송상용,김용일,송상용,김성권,이정상,김상준 대한병리학회 1992 Journal of Pathology and Translational Medicine Vol.26 No.3